Multipotent mesenchymal stem or stromal cells (MSC) have shown to improve outcome of acute renal injury models, but whether MSC can delay renal failure in chronic kidney disease is not known. We injected primary MSC or saline into mice that lack the a3-chain of type IV collagen (COL4A3), a model of chronic kidney disease with close similarities to human Alport disease. Weekly injections of MSC from week 6 to 10 of life prevented the loss of peritubular capillaries and reduced markers of renal fibrosis, that is, interstitial volume, numbers of smooth muscle actin-positive interstitial cells, and interstitial collagen deposits as compared to saline-injected COL4A3-deficient mice. However, renal function, that is, blood urea nitrogen, creatinine levels, proteinuria as well as survival of COL4A3-deficient mice were not affected by MSC injections. Although MSC were found to localize to kidneys of COL4A3-deficient mice after injection, differentiation into renal cells was not detected. However, MSC expressed growth factors, that is, vascular endothelial growth factor (VEGF) and bone morphogenetic protein-7 under basal culture conditions. In fact, VEGF mRNA levels were increased in kidneys of MSC-injected COL4A3-deficient mice and MSC supernatants enhance endothelial cell proliferation in vitro. Thus, weekly injections with MSC prevent loss of peritubular capillaries possibly owing to local production of growth factors rather than by differentiation into renal cells. The maintenance of interstitial vasculature is associated with less interstitial fibrosis but, is insufficient to delay renal failure and survival of COL4A3-deficient mice.
Stem cells have been proposed as a new opportunity for the treatment of many diseases. In view of ethical concerns regarding the use of embryonic stem cells, adult stem cells, for example, bone marrow-derived and fibroblast-like plasticadherent mesenchymal stem cells or their closely related counterpart, multipotent mesenchymal stromal cells (MSCs), may represent a valuable substitute. 1 MSCs reside in the bone marrow's non-hematopoietic stromal compartment and can be isolated using selection owing to plastic adherence. 2 MSCs produce growth factors and cytokines that support hematopoiesis in vivo and in vitro, but MSC can also differentiate into a wide variety of cell lineages. 3 In rodents, injections with MSC have proven beneficial in either toxic or ischemic tubular necrosis, [4] [5] [6] ischemic limb, or heart disease. 7, 8 Less well-defined bone marrow-derived cells reconstitute the mesangium after mesangiolysis. 9 However, the effects of MSC observed in acute and potentially reversible models of mesangial or tubular injury may not apply to chronic kidney disease. 10 In the fibrotic kidney, MSC could also promote fibrogenesis-associated progression of tubulointerstitial damage similar to what has been observed in obstructive nephropathy or the fibrotic lung. 11, 12 To date, the effect of MSCs on the progression of chronic kidney disease is unknown. 13 We addressed this question by preparing primary murine MSCs that were injected into mice deficient for the a3-chain of type IV collagen (COL4A3). These mice are characterized by an abnormal assembly of glomerular basement membranes similar to human Alport disease. 14, 15 COL4A3-deficient mice represent a model for chronic kidney disease associated with interstitial fibrosis and uremia-related death around 10 weeks of age. 14, 16 We show that injected MSC localize to kidneys of COL4A3-deficient mice, but remain within peritubular capillaries and do not transdifferentiate into renal cells. MSCs prevent the loss of peritubular capillaries and interstitial fibrosis, which, however, is not associated with prolonged survival of COL4A3-deficient mice.
RESULTS

Distribution and fate of intravenously injected MSC in COL4A3-deficient mice
In order to determine their intrarenal distribution MSCs were labeled with a red fluorescent dye and kidneys of 6-and 9.3-week-old COL4A3-deficient mice were obtained 3 days after intravenous injection. Labeled MSCs were found to locate to the renal cortex outside the tubular compartment, which was apparent by costaining renal epithelial cells for cytokeratin and laminin for which costaining with MSCs was not observed (Figure 1a and b) . Staining renal endothelial cells with an MECA-32-specific antibody revealed that MSCs localized within peritubular capillaries (Figure 1c) . MSCs neither colocalized with MECA-32 ( Figure 1c ) nor were MSCs detected in the glomeruli of COL4A3-deficient mice (not shown). Costaining with a Ki-67-specific antibody addressed the question of MSC proliferation in kidneys of COL4A3-deficient mice. The intrarenal MSC (10%) stained positive for Ki-67 ( Figure 1d ). Next, we intended to assess the fate of MSCs that distribute to peritubular capillaries. For this purpose, fluorescently labeled MSCs were injected at various intervals before being killing at 9.3 weeks of age. Two hours after injection, 11.072.1 MSCs were detected per high power field in kidneys of COL4A3-deficient mice ( Figure 2 ). Three and 7 days after injection, the number of MSCs in peritubular capillaries had declined to 6.771.6 and 4.471.2 MSCs/high power field, respectively ( Figure 2 , n ¼ 6-8/ group). MSCs injected into 6-week-old COL4A3-deficient mice were detected at very low numbers in the renal interstitium, indicating that MSC recruitment increases in more advanced stages of kidney disease.
MSCs prevent interstitial fibrosis in COL4A3-deficient mice
We hypothesized that recruitment of injected MSCs to the kidney would modulate renal pathology of COL4A3-deficient mice. Thus, COL4A3-deficient mice were killed at the age of 9.3 weeks after 4 weekly injections of MSCs or saline for collection of renal tissue.
Glomerular injury. Saline-injected COL4A3-deficient mice had diffuse glomerulosclerosis as compared to age-matched wild-type control mice ( Figure 3 , Table 1 ). Glomerulosclerosis was characterized by segmental or global increase of glomerular matrix, adhesions to Bowman's capsule, or crescent formation. Injections with MSC did not affect the percentage of either segmental or global glomerulosclerosis or the number of Mac2-positive glomerular macrophages in COL4A3-deficient mice (Table 1, Figure 3) .
Interstitial fibrosis. COL4A3-deficient mice showed diffuse interstitial fibrosis when compared to wild-type mice ( Figure 4 ). This was evident from quantitative morphometry, as saline-injected COL4A3-deficient mice showed an increase of the respective indices for interstitial volume, interstitial collagen, and smooth muscle actin-positive area as compared to wild-type mice ( Figure 4 , Table 1 ). MSCs significantly reduced all these markers compared to vehicle-treated COL4A3-deficient mice (Figure 4) . In saline-injected COL4A3-deficient mice interstitial fibrosis was associated with markedly reduced numbers of peritubular capillary cross-sections. MSC injection partially restored the density of peritubular capillaries as compared to wild-type mice (Table 1, Figure 3 ). Interstitial fibrosis in COL4A3-deficient mice was associated with an increased number of interstitial Mac2-positive macrophages when compared to saline-treated mice. MSC injection did not affect the numbers of interstitial Mac2-positive macrophages as compared to saline-treated COL4A3-deficient mice ( Figure 3 , Table 1 ).
Renal function. COL4A3-deficient mice had proteinuria consistent with their diffuse glomerulosclerotic lesions ( Figure 5 ). Weekly injections with MSC from week 6 to 9 did not affect protein/creatinine ratios in urines compared to saline-treated mice at week 9 ( Figure 5 ). No statistical Table 1 , original magnification Â 100-200. Dotted circles indicate the glomeruli. o r i g i n a l a r t i c l e significant differences were noted in blood urea nitrogen in saline-and MSC-treated COL4A3-deficient mice at week 9 ( Table 1) . Although serum creatinine levels determined by the Jaffe method can overestimate creatinine levels in mice, 17 no significant difference was detected in serum creatinine levels in saline-and MSC-treated COL4A3-deficient mice at week 9 (Table 1 ). These data show that MSCs can prevent loss of peritubular capillaries and interstitial fibrosis, but not glomerulosclerosis, proteinuria, and renal failure in COL4A3-deficient mice.
Survival of COL4A3-deficient mice injected with MSC
Next, we studied the effects of MSC injection on survival of COL4A3-deficient mice treated with either MSC or saline. Saline-treated COL4A3-deficient mice showed a mean survival of 75 days (95% confidence interval 68-82 days), whereas weekly injections with MSC from week 6 to 9 had a mean survival of 84 days (95% confidence interval 76-93 days). Kaplan-Meier analysis using log-rank two-tailed testing revealed a P ¼ 0.16, indicating that MSC injections did not significantly affect survival of COL4A3-deficient mice ( Figure 6 ). Mortality of COL4A3-deficient mice was likely to be related to uremic death as within the last week of life the physical activity of COL4A3-deficient mice continuously declined until death as noted in previous studies. 16, 18 Wild-type control mice remained healthy until the end of the study.
MSC express basal levels of VEGF and BMP-7
As we did not observe MSC differentiation into renal cells in kidneys of COL4A3-deficient mice, paracrine secretion of mediators, for example, cytokines or growth factors, may represent another mechanism how MSC cells modulate local tissue injury. For example, small amounts of bone morphogenetic protein (BMP)-7 and vascular endothelial growth factor (VEGF) have been shown to have strong modulatory effects on the progression of renal injury. 19, 20 In fact, MSCs cultured for 24 h either with or without fetal calf serum expressed significant levels of growth factors, that is, VEGF and BMP-7 mRNA (Figure 7a ). Next, we hypothesized that the microenvironment of a chronically injured kidney may modulate MSC gene expression and growth factor production. In order to address this issue, we examined the gene expression profile of MSCs cultured without serum using 430 Affymetrix gene array. MSCs were incubated with supernatants of cells prepared from kidneys of either 9.3-week-old healthy wild-type mice or diseased COL4A3-deficient mice (n ¼ 3). After 12 h of incubation, MSCs were harvested and total RNA was prepared for gene array analysis. The analysis intended to identify genes differentially expressed by MSCs exposed to either a nephritic or a non-nephritic cytokine environment. The correlation coefficient between the two culture conditions for the expression of each gene was greater than 0.975 (Figure 7b) . Comparison of the gene expression profiles of MSCs exposed to healthy or diseased kidney supernatants showed that no genes were statistically significantly differentially expressed (Figure 8 ). Thus, 12 h exposure of MSCs to supernatants of kidney cells prepared from COL43A-deficient mice does not modulate the gene expression profile of MSC.
Expression of VEGF and BMP-7 in kidneys of COL4A3-deficient mice
In order to test whether kidneys of MSC-treated COL4A3-deficient mice show higher expression levels of the a forementioned growth factors, we performed real-time reverse transcription-polymerase chain reaction (RT-PCR) for mRNAs of VEGF and BMP-7 on total RNA isolates from COL4A3-deficient mice that had been injected with MSCs or saline 7 days before being killing. MSC-injected kidneys expressed twofold higher levels of VEGF mRNA compared to saline-injected COL4A3-deficient mice; however, this did not reach statistical significance (Figure 8 ). BMP-7 mRNA levels were comparable in both groups. These data suggest that MSCs prevent the loss of peritubular vasculature in association with increased VEGF levels in kidneys of COL4A3-deficient mice.
Soluble factors released by MSCs induce endothelial cell proliferation
The observation that MSC injection maintains the peritubular capillary network in COL4A3-deficient mice can either be explained by enhanced endothelial cell proliferation or reduced endothelial cell death. To address this question, we coincubated a murine endothelial cell line with supernatants of either MSC, cultured under starving conditions, or VEGF under serum-free conditions. MSCs and VEGFs both markedly increased endothelial cell proliferation ( Figure 9 ). In addition, we asked whether MSC supernatants effects improve EC survival under serum-free culture conditions. Using identical culture conditions, endothelial cell death was determined by costaining for propidium iodine and annexin 5. MSC and tubular cell supernatants both did not affect the percentage of apoptotic or necrotic endothelial cells after 24 h of incubation (data not shown). These data suggest that soluble factors released by MSCs increase endothelial cell 
Discussion
Injection of cultured MSCs can have beneficial effects on experimental models of acute kidney disease, 4-6 but their effects on chronic kidney disease is unknown. We used COL4A3-deficient mice as a model of chronic kidney disease associated with interstitial fibrosis and renal failure.
MSCs prevent interstitial fibrosis, but do not prolong survival of COL4A3-deficient mice
Morphometry revealed that MSC injections reduced interstitial volume in COL4A3-deficient mice. In adult COL4A3-deficient mice, the interstitial compartment consists of the peritubular vasculature, myofibroblasts, interstitial matrix, and immune cell infiltrates. 16 Numbers of interstitial macrophages were comparable in both groups. By contrast, collagen deposits and the smooth muscle actin-positive area were reduced in the renal interstitium of MSC-vs salineinjected COL4A3-deficient mice. Thus, the reduced interstitial volume in MSC-injected COL4A3-deficient mice relates to a decreased number of interstitial myofibroblasts and collagen deposits. Renal fibroblast proliferation and matrix production are driven by renal ischemia. 21 In fact, the numbers of peritubular capillaries increased with MSC injections as determined by immunostaining for the endothelial cell marker MECA32. MSC have shown to enhance neoangiogenesis and tissue repair in ischemic skeletal muscle, 7 myocardium, 8, 22 and kidney. 6 Thus, the proangiogenic effects of injected MSC may prevent loss of peritubular capillaries and subsequent fibroblast proliferation and matrix production in the renal interstitium of COL4A3-deficient mice. Although the extent of interstitial fibrosis is considered to be a major factor of progression in chronic kidney disease, MSC-related reduction of interstitial fibrosis did not delay renal failure in COL4A3-deficient mice. These data are consistent with a recent study that found progression to uremic death of COL4A3-deficient mice to be independent of the extent of interstitial fibrosis. 23 In this study, blockade of tumor growth factor (TGF)-b reduced myofibroblast proliferation and interstitial matrix deposition, which did not result in prolonged survival of COL4A3-deficient mice. Obviously, in COL4A3-deficient mice, interstitial fibrosis is a marker of chronic kidney disease, but progressive loss of renal function is driven by other factors. For example, previous studies have identified integrin-a1b1, angiotensin II, vasopeptidase, and chemokine receptor CCR1-dependent interstitial macrophage recruitment as factors that contribute to the progression of kidney disease in COL4A3-deficient mice. 18, [23] [24] [25] Given the low number of MSCs recruiting to the renal interstitium of 6-week-old COL4A3-deficient mice, it is rather unlikely that an earlier onset of MSC injections may have shown different results. Thus, our data argue for a limited role of MSC injections in chronic kidney disease.
MSCs neither differentiate into tubular cells nor change their gene expression profile in a chronically diseased kidney microenvironment
The MSCs we used in our experiments have the capacity to differentiate into multiple cell lineages, for example, skeletal muscle cells, and hematopoietic cells. 7, 26 However, when MSCs were injected into mice after ligation of the femoral artery neoangiogenesis was markedly enhanced in the absence of MSC differentiation into for example, endothelial cells. 7 Data from two different models of acute tubular necrosis suggested that injected MSCs contribute to tubular regeneration by differentiation into tubular epithelial cells. 4, 5 Our results show that MSCs do not differentiate into renal cells in kidneys of COL4A3-deficient mice. MSCs were found at considerable numbers within peritubular capillaries, but not in the interstitial, tubular, or glomerular compartment. The latter may relate to the lack of chemokine receptor CCR5 in MSC, which is required for the recruitment of leukocytes to glomeruli and transendothelial diapedesis. 27 In fact, differentiation into tubular epithelial cells or interstitial cells would require that MSC migrate from the intravascular into the tubular or interstitial compartment of the kidney. However, MSCs remained up to 7 days within peritubular capillaries. Furthermore, their intravascular distribution and their lack of MECA-32 expression argue against differentiation of MSCs into endothelial cells of peritubular capillaries. This finding is consistent with a recent study that injected primary MSCs into rats with ischemic acute tubular necrosis. 6 Within 3 days after administration, none of the intrarenal MSCs had differentiated into a tubular or endothelial cell phenotype. Two recently published studies using either Y-chromosome-or GFP-transgenic-based detection systems also failed to detect stem cell differentiation into tubular cells as a repair mechanism in ischemic tubular injury. 28, 29 In view of the studies reported from Morigi and Herrera, the data regarding stem cell differentiation in kidney disease are currently under debate. 30 Obviously, MSCs can modulate tissue injury through different mechanisms, for example, the production of growth factors. Togel et al. 6 reported that 24 h after ischemic injury renal mRNA levels of growth factors, that is, basic fibroblast growth factor, VEGF, TGF-a, and Bcl-2 were upregulated in kidneys of MSC-injected mice. We determined mRNA levels of VEGF and BMP-7 in kidneys of 9.3-week-old COL4A3-deficient mice. We found small increases of VEGF mRNA levels in MSC compared to the saline-injected COL4A3-deficient mice. Cultured MSCs showed basal expression of VEGF and BMP-7, which was not affected by exposing MSCs to the cytokine environment of diseased COL4A3-deficient mice. These data suggest that injected MSCs secrete growth factors into the renal interstitium of COL4A3-deficient mice. In fact, MSC supernatants increase the proliferation of cultured endothelial cells under serum-free conditions. For example, VEGF, a proangiogenic factor protects the loss of peritubular vasculature in chronic kidney disease. 31 Administration of VEGF in the remnant kidney model increased endothelial cell proliferation in peritubular capillaries and reduced interstitial fibrosis. 19 Accordingly, increased VEGF mRNA levels were associated with increased numbers of peritubular capillaries in MSC-injected COL4A3-deficient mice. An additional role may have BMP-7 that is released by MSCs. BMP-7 is a member of the TGF-b superfamily with proven antifibrotic effects in models of chronic kidney disease. 20 For example, exogenous BMP-7 improved interstitial fibrosis and tubular injury in mice with nephrotoxic serum nephritis. 32 However, we were unable to detect a significant increase in renal BMP-7 mRNA levels associated with MSC injection in COL4A3-deficient mice, which may also relate to the low number of intrarenal MSCs 1 week after the last MSC injection. Together, these data argue in favor of MSC basal expression of growth factors that prevent loss of peritubular vasculature and interstitial fibrosis in COL4A3-deficient mice with Alport disease.
In summary, in COL4A3-deficient mice injected MSCs distribute to peritubular capillaries but do not differentiate into renal cells and almost completely disappear from the kidney within a period of 7 days. Weekly MSC injections prevent the loss of peritubular capillaries and interstitial fibrosis in COL4A3-deficient mice, potentially owing to their basal secretion of proangiogenic factors such as VEGF. However, these effects are insufficient to delay renal failure in COL4A3-deficient mice. As loss of renal function is independent of interstitial fibrosis in COL4A3-deficient mice, interstitial fibrosis may rather be a marker than a factor for progression of chronic kidney disease.
MATERIALS AND METHODS Preparation of bone marrow-derived MSCs
MSCs were prepared from the bone marrow of female mice as described previously for peripheral blood-derived and fibroblastlike, plastic-adherent cells. 7, 26 Briefly, the murine femur was rinsed and mononuclear cells were cultured in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum in standard tissue cell culture dishes until an adherent and confluent cell layer was established. Fibroblast-like and plastic-adherent cells were carefully removed by ethylenediaminetetraacetic acid-trypsin digestion and characterized at different culture passages by the surface expression of a standard antibody panel in flow cytometry. According to a recent preposition on the nomenclature for MSCs, 2 the appropriate term for these cells would be multipotent mesenchymal stromal cells (MSCs), although true stem cell features for these cells cannot be excluded at present. The primary MSCs between passages 4 and 6 in culture were exclusively CD14
þ , CD105, and major histocompatibility complex class II À , like other already published MSC-type cell lines. 7, 26 Some preparations of MSCs were labeled with PKH26 (Red Fluorescent Cell Linker Kit, Sigma-Aldrich Chemicals, Steinheim, Germany). Labeling efficacy was assessed by flow cytometry to be 497%. Viability assessed by Trypan blue exclusion was 490%. For in vitro studies, MSCs were cultured without fetal calf serum for 24 h before use.
Animal studies COL4A3-deficient mice on a 129/SvJ genetic background were bred under specific-pathogen-free housing conditions as described. 18 The genotype of each mouse was confirmed by PCR using genomic DNA extracted from tail tips. COL4A3-deficient mice develop glomerulosclerosis and renal fibrosis and progress to uremia-related death at about 10 weeks of age. 16 At 6 weeks of age, COL4A3-deficient mice were divided into two groups that received tail vein injections of either 1 Â 10 6 MSC in 200 ml isotonic saline or saline only at weekly intervals. Treatment was continued until death for assessment of survival or until day 66 of age (9.3 weeks) in a subgroup of mice that were killed for histopathological evaluation. Urine samples were obtained at weekly intervals and analyzed for protein/creatinine ratios using an automatic autoanalyzer (Integra 800, Roche Diagnostics, Germany) as described. 24 Blood was drawn from the retro-orbital sinus under general anesthesia before being killing. Serum was analyzed for creatinine (Jaffe method) and blood urea nitrogen using an automatic analyzer as above. In order to assess the organ distribution injected MSC groups of 6-and 9.3-week-old COL4A3-deficient mice were killed at various intervals after injection with MSCs that had been labeled with PKH26 (Red Fluorescent Cell Linker Kit, Sigma-Aldrich Chemicals, Steinheim, Germany). Labeling efficacy was assessed by flow cytometry before injection.
Histopathological evaluation
Renal tissue was obtained after 3 days, snap frozen, and prepared for fluorescence microscopy. Costaining on frozen sections was performed using the following primary and secondary antibodies: mouse anti-cytokeratin 18 (Chemicon International, Hampshire, UK, clone RGE53, 1:50) with a fluorescein isothiocyanate (FITC)-labeled anti-mouse immunoglobulin (Ig) G1 antibody for detection (Dianova, Hamburg, Germany; clone H143.225.8, 1:100); rabbit anti-laminin (Abcam, Cambridge, UK; 1:25) with an FITC-labeled anti-rabbit IgG antibody for detection (Abcam; 1:50); rat anti-Ki-67 DAKO, Hamburg, Germany; (clone TEC-3, 1:25) with an FITClabeled anti-rat IgG antibody for detection (Linaris, WertheimBettingen, Germany; 1:50). From each mouse parts of the kidneys were fixed in 10% formalin and embedded in paraffin. Sections (2 mm) were stained with periodic acid-Schiff reagent or silver following the instructions of the supplier (Bio-Optica, Milano, Italy). Glomerular sclerotic lesions were assessed using a semiquantitative score by a blinded observer as follows: 0 ¼ no lesion; 1 ¼ o25% sclerotic; 2 ¼ 25-49% sclerotic; 3 ¼ 50-74% sclerotic; and 4 ¼ 75-100% sclerotic, respectively. Fifteen glomeruli were analyzed per section. The indices for interstitial volume and interstitial
collagen deposition were determined as described previously. 33 The following primary antibodies were used for immunostaining as described:
24 rat anti-Mac-2 (Cedarlane, Ontario, Canada; macrophages, 1:50), anti-mMECA-32 (Iowa Hybridoma Bank, USA; endothelial cells, 1:50), and mouse anti-smooth muscle actin (DAKO, Carpinteria, CA, USA; myofibroblasts, clone 1A4, 1:100). Interstitial cell counts were determined in 15 high power fields by a blinded observer. For the quantification of the interstitial smooth muscle actin-positive area digital pictures were analyzed as described previously. 24 Preparation and culture of renal cells Kidneys from either COL4A3-deficient or wild-type mice were manually dissected in a RPMI-1640 medium (GIBCO/Invitrogen, Carlsbad, CA, USA) plus 10% fetal calf serum and cultured at 371C for 48 h. Cell supernatants were obtained after centrifugation for 3 min at 1000 r.p.m. and added to cultured primary MSCs for 12 h at 371C. MSCs total RNA was extracted using a 'Qiagen RNeasy Mini kit' (Qiagen Science, Germantown, MD, USA) according to the protocol provided by the manufacturer.
In vitro studies with endothelial cells Murine renal endothelial cells (GENC-clone 7) were cultured in Dulbecco's Modified Eagle's Medium (GIBCO/Invitrogen) containing 10% fetal calf serum for 48 h at 371C. 34 Cells were splitted and kept in the medium without fetal calf serum 36 h prior incubation with supernatants of either MSC (1:5) or VEGF in the medium (20 ng/ml) for 24 h. MSCs used for that experiment were cultured without fetal calf serum for 24 h. Proliferation of endothelial cells was assessed using CellTiter 96 Proliferation Assay by adding 20 ml CellTiter 96 Aqueous One Solution to each well and kept for 1.5 h at 371C (Promega, Mannheim, Germany). The optical density was measured at 620 nm. Endothelial cell death was assessed by flow cytometry after staining with propidium iodide and anti-Annexin V-FITC (Annexin V-FITC apoptosis detection kit, BD Biosciences Pharmingen, San Diego, CA, USA).
Real-time quantitative RT-PCR and Affimetrix chip microarray profiling For real-time RT-PCR kidney aliquots from each mouse or cultured cells were snap frozen in liquid nitrogen and stored at À801C. RNA preparation and real-time RT-PCR were performed as described. 33 The following oligonucleotide primers (300 nM) and probes (100 nM) were used: murine Vegf -forward, 5
0 -GCTGTGCA GGCTGCTGTAAC-3 0 , reverse, 5 0 -TGATGTTGCTCTCTGACGTGG-3 0 ; internal fluorescence-labeled probe (FAM)-5 0 -ATGAAGCCCTG GAGTGCGTGCC-3 0 ; and murine Bmp7 -predeveloped reagent. All primers and probes were obtained from PE Biosystems (Weiterstadt, Germany).
Microarray experiments were carried out with total RNA from cultured primary MSCs that had been incubated with supernatants of kidney cell suspensions of either 9.3-week-old COL4A3-deficient or wild-type mice for 12 h. Total RNA (6 mg) from three independent preparations in each group were used for biotinlabeled cRNA probe synthesis and hybridization of MOE 430Av2 arrays according to the Affymetrix Expresssion Analysis Technical Manual (www.affymetrix.com). Triplicate arrays were scanned and analyzed using the Affymetrix GeneChip Operating software (GCOS 1.0). Each array was checked for general assay quality (3 0 -5 0 ratios for glyceraldehyde-3-phosphate dehydrogenase and b-actin o1.1, average background o75 fluorescence units, and scaling factors within a two-fold range). Background corrected and normalized expression measures from probe level data (cel-files) were obtained by using the robust multichip average function implemented in Bioconductor's affy-package (http://www.bioconductor.org). 35 
Statistical analysis
Data are presented as mean7s.e.m. Paired Student's t-test was used for the comparison of groups. A value of Po0.05 was considered to indicate statistical significance. Survival curves were compared by Kaplan-Meier analysis using log-rank two-tailed testing. For microarray data, multiple testing-adjusted statistical significance of the probability for differential expression was assessed by the permutation-based method of Tusher et al. 36 as implemented in the Bioconductor Siggenes package.
